Considerations for the nonclinical safety evaluation of antibody drug conjugates for oncology.
Roberts SA, Andrews PA, Blanset D, Flagella KM, Gorovits B, Lynch CM, Martin PL, Kramer-Stickland K, Thibault S, Warner G.
Roberts SA, et al. Among authors: martin pl.
Regul Toxicol Pharmacol. 2013 Dec;67(3):382-91. doi: 10.1016/j.yrtph.2013.08.017. Epub 2013 Sep 5.
Regul Toxicol Pharmacol. 2013.
PMID: 24012707